Loading...

TYRA - Tyra Biosciences, Inc.

Analyst Coverage Initiated Signal for 06-23-2022
Analyst Coverage Initiated: TYRA rating Buy by H.C. Wainwright
Price Target: $12



Stock Signal Information


Signal

Analyst Coverage Initiated Stock
Report Date: 06-23-2022
Symbol: TYRA - Tyra Biosciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: TYRA rating Buy by H.C. Wainwright
Price Target: $12

  TYRA Technical Chart

Company Contact

Tyra Biosciences, Inc. (TYRA)
2656 State Street
Carlsbad, CA
Phone: 619-728-4760
Website: http://www.tyra.bio
CEO:


Company Profile

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.